Prosecution Insights
Last updated: November 20, 2026

Sergio Coffa, USPTO Patent Examiner

Listed by the USPTO as COFFA, SERGIO

Tech Center 1600 • Art Units: 1654 1658 1671 1675 1676

This examiner grants 61% of resolved cases

Analysis

COFFA, SERGIO is assigned to tech center 1600 and art unit 1654. The record includes 760 resolved cases, with an allowance rate of 61.2%. The median time to allowance is 1072 days, giving applicants a substantial historical reference for prosecution duration.

The interview lift is 32.3%, indicating a positive association between interviews and allowance outcomes. The listed companies are Axoltis Pharma, Novo Nordisk A/S, and Takeda Pharmaceutical Company Limited. The recurring firms are FOLEY & LARDNER LLP, LICATA & TYRRELL P.C., and Muncy, Geissler, Olds & Lowe, P.C. The large record supports using the figures for planning context, while application-specific claim and prior-art analysis remains essential.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Performance Statistics

61.2%
Allow Rate
+1.2% vs TC avg
823
Total Applications
+32.3%
Interview Lift
1072
Avg Prosecution Days
Based on 760 resolved cases, 2023–2026

Rejection Statute Breakdown

3.8%
§101 Eligibility
16.7%
§102 Novelty
34.4%
§103 Obviousness
27.2%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
19463848 SEMAGLUTIDE IN MEDICAL THERAPY Final Rejection Novo Nordisk A/S
18686954 FUNCTIONALIZED, DECELLULARIZED CORNEAL EXTRACELLULAR MATRIX HYDROGELS FOR OCULAR TISSUE TREATMENT Non-Final OA THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
18316988 TREATMENT OF PATIENTS WITH SEVERE VON WILLEBRAND DISEASE UNDERGOING ELECTIVE SURGERY BY ADMINISTRATION OF RECOMBINANT VWF Non-Final OA Takeda Pharmaceutical Company Limited
18833263 DISRUPTION OF SONIC HEDGEHOG-SURF4 INTERACTION FOR CANCER TREATMENT Non-Final OA The Hong Kong University of Science and Technology
18257483 COMPOSITIONS AND METHODS FOR MODULATING MYC EXPRESSION Final Rejection FLAGSHIP PIONEERING INNOVATIONS V, INC.
18553437 ANGIOGENESIS INHIBITING PEPTIDE AND USE THEREOF Non-Final OA SEOUL NATIONAL UNIVERSITY HOSPITAL
18571666 A NOVEL COMPOUND ACTING AGAINST A SELECT GROUP OF BACTERIA Non-Final OA Northeastern University
18580752 PEPTIDE, COMPOSITION FOR RECOVERING RARE EARTH ELEMENTS COMPRISING SAME, AND RECOVERY METHOD Non-Final OA GWANGJU INSTITUTE OF SCIENCE AND TECHNOLOGY
17767734 IFIT Polypeptides and Uses for Treating Tuberculosis Infection Non-Final OA Stellenbosch University
17518047 METHOD FOR TREATING OPIOID USE DISORDER Final Rejection The United States Government as represented by the Department of Veterans Affairs
17267652 COMPOUNDS USEFUL FOR THE TREATMENT AND/OR CARE OF THE SKIN, HAIR, NAILS AND/OR MUCOUS MEMBRANES Final Rejection LUBRIZOL ADVANCED MATERIALS, INC.
18262113 USE OF LINK-TSG6 FOR THE TREATMENT OF OSTEOARTHRITIC PAIN Non-Final OA The University of Manchester
16610826 STABLE INSULIN FORMULATIONS Final Rejection Arecor Limited
18561469 KIDNEY ACTIVE FUSION PROTEINS AND METHODS OF TREATMENT USING THE SAME Non-Final OA Alexion Pharmaceuticals, Inc.
18280632 Methods and Compositions for Treatment of Disease Final Rejection Coya Therapeutics, Inc.
18577588 IL1RA DERIVED PEPTIDES FOR TREATMENT OF DIABETIC NEPHROPATHY Non-Final OA SERODUS APS

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Who Appears Before This Examiner

Top companies before this examiner

Law firms appearing most often

Frequently Asked Questions

What is examiner Sergio Coffa's allowance rate?

61.2% of resolved applications examined by Sergio Coffa were allowed (760 resolved cases), compared with 48.2% across Art Unit 1654 over the last five years.

Does an interview help with examiner Sergio Coffa?

This examiner's interview lift is +32.3 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.

How long does examiner Sergio Coffa take to allow a patent?

Applications allowed by Sergio Coffa took 1,072 days on average from filing to allowance.

Which art unit does examiner Sergio Coffa work in?

Sergio Coffa examines applications in Art Unit 1654 in Tech Center 1600 (Biotechnology & Pharmaceuticals).

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month